CoChat

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis

Open access
Xu, Hongjiao, Zhao, Qian, Song, Nazi, Yan, Zhibin, Lin, Runfeng, Wu, Shuohan, Jiang, Lili, Hong, Sihua, Xie, Junqiu, Zhou, Huihao, Wang, Rui, Jiang, Xianxing · 2020 · Nature Communications
Cited by 148

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Chronic nonalcoholic steatohepatitis (NASH) is a metabolic disorder that often leads to liver fibrosis, a condition with limited therapy options. Adiponectin is an adipocytokine that regulates glucose and lipid metabolism via binding to its receptors AdipoR1 and AdipoR2, and AdipoRs signaling is reported to enhance fatty acid oxidation and glucose uptake. Here, we synthesize and report an adiponectin-based agonist JT003, which potently improves insulin resistance in high fat diet induced NASH mice and suppresses hepatic stellate cells (HSCs) activation in CCl 4 induced liver fibrosis. Mechanistic studies indicate that JT003 simultaneously stimulates AdipoR1- and AdipoR2- mediated signaling pathways as well as the PI3K-Akt pathway. Moreover, JT003 treatment significantly improves ER-mitochondrial axis function, which contributes to the reduced HSCs activation. Thus, the AdipoR1/AdipoR2 dual agonist improves both NASH and fibrosis in mice models, which provides the pharmacological and biological foundation for developing AdipoRs-based therapeutic agents on liver fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19668-y

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 38

  1. Wesolowski, S. R., Kasmi, K. C., Jonscher, K. R. & Friedman, J. E. Developmental origins of NAFLD: a womb with a clue. Nat. Rev. Gastroenterol. Hepatol. 14, 81–96 (2017). · DOI · Paper page
  2. Musso, G., Cassader, M. & Gambino, R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 15, 249–274 (2016). · DOI · Paper page
  3. Friedman, S. L. Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH. Nat. Rev. Gastroenterol. Hepatol. 10, 71–72 (2013). · DOI
  4. Nassir, F. & Ibdah, J. A. Role of mitochondria in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15, 8713–8742 (2014). · DOI · Paper page
  5. Baiceanu, A., Mesdom, P., Lagouge, M. & Foufelle, F. Endoplasmic reticulum proteostasis in hepatic steatosis. Nat. Rev. Endocrinol. 12, 710–722 (2016). · DOI · Paper page
  6. Filozof, C., Goldstein, B. J., Williams, R. N. & Sanyal, A. Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 75, 1373–1392 (2015). · DOI · Paper page
  7. Ratziu, V. et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55, 419–428 (2012). · DOI · Paper page
  8. Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. & Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746–26749 (1995). · DOI · Paper page
  9. Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98, 2005–2010 (2001). · doi:10.1073/pnas.98.4.2005 · Paper page
  10. Tanabe, H. et al. Crystal structures of the human adiponectin receptors. Nature 520, 312–316 (2015). · DOI · Paper page
  11. Vasiliauskaité-Brooks, I. et al. Structural insights into adiponectin receptors suggest ceramidase activity. Nature 544, 120–123 (2017). · DOI · Paper page
  12. Tomita, K. et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 48, 458–473 (2008). · DOI · Paper page
  13. Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. 19, 121–135 (2017). · DOI · Paper page
  14. Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720–733 (2015). · DOI · Paper page
  15. Chou, I. P., Lin, Y. Y., Ding, S. T. & Chen, C. Y. Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitate-treated HepG2 cells through the PI3 K/AKT pathway. Eur. J. Nutr. 53, 907–917 (2014). · DOI
  16. Matsuda, S., Kobayashi, M. & Kitagishi, Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol. 2013, 472432 (2013). · DOI · Paper page
  17. Wang, H. et al. Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. Sci. Rep. 6, 19445 (2016). · DOI
  18. Ma, L. et al. A potent peptide as adiponectin receptor 1 agonist to against fibrosis. J. Enzym. Inhib. Med. Chem. 32, 624–631 (2017). · DOI
  19. Min, X. et al. Crystal structure of a single-chain trimer of human adiponectin globular domain. FEBS Lett. 586, 912–917 (2012). · DOI
  20. Otvos, L. et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 11, 90 https://doi.org/10.1186/1472-6750-11-90 (2011). · DOI · Paper page
  21. Kumar, P. et al. Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS ONE 9, e110405 https://doi.org/10.1371/journal.pone.0110405 (2014). · DOI · Paper page
  22. Titchenell, P. M., Lazar, M. A. & Birnbaum, M. J. Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol. Metab. 28, 497–505 (2017). · DOI · Paper page
  23. Rines, A. K., Sharabi, K., Tavares, C. D. J. & Puigserver, P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat. Rev. Drug Discov. 15, 786–804 (2016). · DOI · Paper page
  24. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159–169 (2012). · DOI · Paper page
  25. Filadi, R., Theurey, P. & Pizzo, P. The endoplasmic reticulum-mitochondria coupling in health and disease: molecules, functions and significance. Cell Calcium 62, 1–15 (2017). · DOI · Paper page
  26. Dasarathy, S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology 60, 22–25 (2014). · DOI
  27. Handa, P. et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 60, 133–145 (2014). · DOI · Paper page
  28. Verfaillie, T. et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 19, 1880–1891 (2012). · DOI · Paper page
  29. Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411 (2017). · DOI · Paper page
  30. Yamauchi, T. & Kadowaki, T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 17, 185–196 (2013). · DOI · Paper page
  31. Kersten, S. Integrated physiology and systems biology of PPARalpha. Mol. Metab. 3, 354–371 (2014). · DOI · Paper page
  32. Saxena, N. K. & Anania, F. A. Adipocytokines and hepatic fibrosis. Trends Endocrinol. Metab. 26, 153–161 (2015). · DOI · Paper page
  33. Kamada, Y. et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125, 1796–1807 (2003). · DOI · Paper page
  34. Zhao, Q. et al. Rapeseed protein-derived antioxidant peptide RAP ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Mol. Pharm. 16, 371–381 (2018). · DOI
  35. Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K. & Ueno, H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 128, 138–146 (2005). · DOI · Paper page
  36. Leiva, O. et al. The role of the extracellular matrix in primary myelofibrosis. Blood Cancer J. 7, e525 (2017). · DOI
  37. Xie, J. et al. Antimicrobial activities and action mechanism studies of transportan 10 and its analogues against multidrug-resistant bacteria. J. Pept. Sci. 21, 599–607 (2015). · doi:10.1002/psc.2781
  38. Xie, J. et al. Novel antimicrobial peptide CPF-C1 analogs with superior stabilities and activities against multidrug-resistant bacteria. Chem. Biol. Drug Des. 90, 690–702 (2017). · DOI

Cited by

See all 148

Metadata

Authors
Xu, H., Zhao, Q., Song, N., Yan, Z., Lin, R., Wu, S., Jiang, L., Hong, S., Xie, J., Zhou, H., Wang, R., & Jiang, X.
Venue
Nature Communications
Published
2020-11-16
Volume
11
Issue
1
Pages
5807-5807
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3105465401
Cited by
148
References
15
FWCI
9.68
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. https://app.cochat.ai/papers/10.1038/s41467-020-19668-y
The paper
Xu, H., Zhao, Q., Song, N., Yan, Z., Lin, R., Wu, S., Jiang, L., Hong, S., Xie, J., Zhou, H., Wang, R., & Jiang, X. (2020). AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. Nature Communications. https://doi.org/10.1038/s41467-020-19668-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.